Amyloidosis is a rare protein-related condition that occurs when your body produces too many amyloid proteins, causing damage ...

Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...

Dear Mayo Clinic: My dad was diagnosed with cardiac amyloidosis shortly after his 70th birthday. It’s difficult to pronounce, let alone understand. What is cardiac amyloidosis? Am I at risk if ...

A new study published in the journal of Clinical and Experimental Dermatology showed that for non-nodular primary localized cutaneous amyloidosis (PLCA), laser therapy is recommended, but ...

Opens in a new tab or window Gene-silencing therapy vutrisiran (Amvuttra) graduated to a broad indication in treatment of transthyretin amyloidosis cardiomyopathy, as Alnylam Pharmaceuticals ...

Healio spoke with Joban Vaishnav, MD, director of the Johns Hopkins Comprehensive Amyloidosis Center, about the process of diagnosing amyloidosis, the importance of multidisciplinary care in ...

Researchers found that peristaltic pump flow mechanically breaks supersaturation to induce amyloid formation by hen egg white lysozyme, a-synuclein, amyloid b 1-40, and b2-microglobulin.

Lower skeletal muscle mass was associated with an increased risk for short- and long-term mortality in patients with cardiac amyloidosis (CA). This association was particularly strong with ...